{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.40","value":"151.60"},{"groupId":"OG001","spread":"67.13","value":"202.50"},{"groupId":"OG002","spread":"33.70","value":"172.38"},{"groupId":"OG003","spread":"79.22","value":"214.00"},{"groupId":"OG004","spread":"99.24","value":"242.89"},{"groupId":"OG005","spread":"67.76","value":"233.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.88","value":"-12.90"},{"groupId":"OG001","spread":"58.90","value":"-49.50"},{"groupId":"OG002","spread":"21.75","value":"-17.36"},{"groupId":"OG003","spread":"63.66","value":"2.38"},{"groupId":"OG004","spread":"42.10","value":"-51.11"},{"groupId":"OG005","spread":"36.40","value":"-21.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.76","value":"-58.60"},{"groupId":"OG001","spread":"87.14","value":"-66.83"},{"groupId":"OG002","spread":"38.30","value":"-66.39"},{"groupId":"OG003","spread":"116.67","value":"-23.25"},{"groupId":"OG004","spread":"84.66","value":"-101.88"},{"groupId":"OG005","spread":"43.60","value":"-53.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.61","value":"55.00"},{"groupId":"OG001","spread":"84.62","value":"68.67"},{"groupId":"OG002","spread":"52.82","value":"44.84"},{"groupId":"OG003","spread":"92.68","value":"141.75"},{"groupId":"OG004","spread":"244.50","value":"152.00"},{"groupId":"OG005","spread":"84.26","value":"111.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.14","value":"-44.10"},{"groupId":"OG001","spread":"86.91","value":"-74.75"},{"groupId":"OG002","spread":"37.93","value":"-71.06"},{"groupId":"OG003","spread":"111.10","value":"-28.00"},{"groupId":"OG004","spread":"130.18","value":"-106.29"},{"groupId":"OG005","spread":"60.70","value":"-52.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.48","value":"-44.40"},{"groupId":"OG001","spread":"72.53","value":"-63.25"},{"groupId":"OG002","spread":"43.37","value":"-60.13"},{"groupId":"OG003","spread":"82.11","value":"-21.25"},{"groupId":"OG004","spread":"116.02","value":"-76.14"},{"groupId":"OG005","spread":"64.73","value":"-44.19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"32"}],"units":"Participants"}],"title":"Change from Baseline to Cycle 2 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"33"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG000","title":"RRMM Dose-evaluation: Carfilzomib 56 mg/m²"},{"description":"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG001","title":"RRMM Dose-evaluation: Carfilzomib 70 mg/m²"},{"description":"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG002","title":"RRMM Dose-expansion: Carfilzomib 70 mg/m²"},{"description":"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG003","title":"NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²"},{"description":"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG004","title":"NDMM Dose-expansion: Carfilzomib 70 mg/m²"},{"description":"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.\n\nParticipants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8.","id":"OG005","title":"NDMM Dose-expansion: Carfilzomib 56 mg/m²"}],"paramType":"MEAN","populationDescription":"Participants in the safety analysis set with available data at Baseline and each time point.","reportingStatus":"POSTED","timeFrame":"Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15","title":"Change From Baseline in Platelet Count","type":"PRIMARY","unitOfMeasure":"10^9 cells/L"}